Coming off peptides — risks, rebound, and how to plan the exit

Most peptide content is about getting on. This guide is about getting off — when you can do it cold turkey, when you can't, and what actually happens to your body when you stop.

The short answer: cold turkey is fine for most peptides. The exception is the GLP/GIP class (Tirzepatide, Semaglutide, Retatrutide, Liraglutide), and the answer there isn't "you'll get sick" — it's "your appetite comes back fast and weight regain is the documented norm without a plan."

Here's the breakdown by class.

Healing peptides (BPC-157, TB-500, GHK-Cu, KPV)

Cold turkey: yes.

These don't create dependence, don't downregulate any hormone axis, don't trigger withdrawal. You stop, the peptide clears (BPC-157 in days, TB-500 over a week or two), and you're back to your unaided baseline.

What you'll notice: nothing acute. The injury you were treating either healed (in which case you don't need it) or didn't (in which case you might restart later or pick a different approach). There's no "post-cycle symptom."

What you WON'T notice: any kind of withdrawal. Healing peptides are well-tolerated to stop.

GH-axis peptides (Ipamorelin, CJC-1295, Tesamorelin, Sermorelin, Hexarelin, GHRP-2/6, MK-677)

Cold turkey: yes for most. MK-677 has one caveat.

Stopping these causes your endogenous GH pulse to return to baseline, which is just slightly less than what you had on-cycle. Most users describe this as "sleep is slightly less deep, recovery slightly slower" — not a withdrawal, just a return to your pre-peptide normal.

The MK-677 caveat: appetite drops noticeably after stopping. Users who got used to the appetite stimulation can find the post-cycle period feels off — but it's the absence of a stimulus, not actual withdrawal. Pass within a week.

What's NOT happening: HPG axis suppression (this isn't testosterone), permanent receptor changes, dependence. The receptors fully recover during the standard 4-week off-cycle.

GLP/GIP class (Tirzepatide, Semaglutide, Retatrutide, Liraglutide, Cagrilintide, Mazdutide, Survodutide, Pemvidutide, Petrelintide, Amycretin)

Cold turkey: technically yes, but the "rebound" is the real thing.

This is the class where coming off matters most. Not because you'll have a withdrawal syndrome — you won't. The half-life is long enough that the drug clears gradually over 4-6 weeks naturally. But weight regain is well-documented in the literature, and the cause is straightforward: when GLP-1 / GIP signaling stops, your appetite returns to baseline, and if your behaviors haven't changed, your weight follows.

The clinical data is consistent: roughly two-thirds of weight loss comes back in the year following GLP-class drug discontinuation if there's no maintenance plan. STEP-4 (Semaglutide) and SURMOUNT trials (Tirzepatide) both show this pattern.

Three options for managing the exit:

Option 1 — Stay on a maintenance dose. Drop to the lowest effective dose (often 5mg Tirzepatide, 1.0 mg Semaglutide, 4mg Retatrutide) and hold there indefinitely. Studies show 5mg Tirzepatide maintenance retains ~80% of the loss long-term. This is the most reliable path, and it's what most clinical providers recommend.

Option 2 — Taper down over 6-8 weeks. Step down dose by half every 2 weeks until you're at the starting dose, then stop. Gives appetite time to ramp back up gradually instead of in a wall.

Option 3 — Cold turkey + behavioral plan. Stop the drug, but commit to: tracking calories for 90 days post-stop, lifting 3+ days a week, prioritizing 1g protein per pound of goal body weight. This works for highly disciplined users. Most underestimate how strong the appetite return is.

What you'll notice in the 4-6 weeks after stopping a GLP class drug:

• Hunger returns. Often dramatically. The "food noise" comes back.
• Fullness signals reset to pre-drug levels — you can eat more before feeling full.
• Cravings for previous comfort foods often spike for 2-3 weeks.
• Weight regain begins anywhere from week 2 to week 12, depending on behavioral changes.

What's NOT happening: chemical dependence, acute withdrawal symptoms, hormone shutdown. The drug clears, the appetite returns to your unmedicated baseline. That's it.

Pigmentation (MT-1, MT-2)

Cold turkey: yes. Pigment fades naturally.

Once you stop, pigment doesn't drop overnight — melanin in skin cells stays until the cells turn over (3-6 months). With no UV exposure during this period, pigment fades gradually. With continued UV exposure, you hold it longer.

There's no metabolic withdrawal. The "side effect" of stopping is just losing the cosmetic effect over months.

Libido peptides (PT-141, Kisspeptin)

Cold turkey: yes. These are as-needed compounds.

Both work episodically rather than chronically — used before activity, not daily. There's no "coming off" because there's no chronic dosing. You either take a dose for a specific situation or you don't. No rebound, no withdrawal.

Kisspeptin in HPG-axis modulation (different use case) is run in short courses; stopping returns the axis to baseline within days.

Nootropic peptides (Selank, Semax, DSIP, Cerebrolysin, P-21, FGL, PE-22-28)

Cold turkey: yes, no withdrawal.

These don't create chemical dependence in the way benzodiazepines or stimulants do. The anxiolytic / cognitive effects fade with the half-life of the compound (Selank/Semax: hours; Cerebrolysin: longer with cumulative effect). Users who relied on them for daily focus may find the unaided baseline feels off for a few days, but there's no medical withdrawal.

Longevity / senolytic (Epitalon, Pinealon, Humanin, FOXO4-DRI)

Cold turkey: yes — these are pulsed compounds by design.

Coming "off" is the default state. These are run as 10-30 day pulses with months of off-time between. Stopping is normal.

HGH

Cold turkey: cause real concerns. Tapering preferred.

Recombinant HGH is the one peptide-adjacent compound where coming off is genuinely harder. Long-term users see:

• Subjective return of pre-HGH baseline (less recovery, less sleep depth, more body-comp regression)
• Possible temporary suppression of natural GH if the user was on it long enough — usually recovers within 8-12 weeks
• Joint stiffness and water retention that built up on-cycle resolve over weeks

Most users on legitimate medical HGH taper down over 4-6 weeks rather than stopping abruptly. Off-label users frequently just stop, with the regression effects above.

IGF-1 LR3, MGF, PEG-MGF

Cold turkey: yes for short cycles. Don't run long enough to need a taper.

These are run in 4-week short cycles by design. Stopping is built into the protocol. No withdrawal, no rebound.

Anti-myostatin (Follistatin 344, ACE-031)

Cold turkey: yes.

The anabolic effect (which was modest to begin with) fades. No metabolic withdrawal.

Immune (Thymosin Alpha-1, LL-37, KPV, VIP)

Cold turkey: yes, but with VIP exception.

For Tα1, KPV, LL-37 — stop and the immune-modulating effect fades over weeks. No withdrawal.

For VIP in the Shoemaker CIRS protocol specifically — stopping mid-protocol can cause symptom relapse if the underlying mold/biotoxin issue isn't fully addressed first. Not a withdrawal; a relapse of the underlying condition VIP was managing.

Metabolic (MOTS-c, SS-31, 5-Amino-1MQ)

Cold turkey: yes.

Subtle compounds with no dependence profile. Stop and you return to baseline.

When NOT to come off

Some peptides are running for medical reasons where stopping has clinical consequences. If you're on these, talk to your provider before stopping:

• Tesamorelin (Egrifta) for HIV-associated lipodystrophy
• Setmelanotide (Imcivree) for monogenic obesity
• Teriparatide (Forteo) for severe osteoporosis (also has FDA's 24-month lifetime cap — stopping at the cap is mandatory)
• Octreotide (Sandostatin) for acromegaly / carcinoid / VIPoma — stopping causes return of the underlying disease symptoms
• Pramlintide (Symlin) if used with insulin — stopping requires re-titrating insulin doses

These aren't peptides where "I want to take a break" is a decision to make alone. The underlying medical condition continues whether or not you take the drug.

How to plan the exit

For everything except the GLP/GIP class:

1. Pick a stop date. 2. Take your last dose on schedule. 3. The drug clears. Receptors normalize over 4 weeks (the standard cycle break). 4. Reassess at week 8 whether you want to restart, switch peptides, or stay off.

For the GLP/GIP class specifically:

1. Decide on Option 1 (maintenance) vs Option 2 (taper) vs Option 3 (cold turkey + behavior plan) BEFORE you stop. 2. If Option 2 or 3: track weight weekly for 12 weeks post-stop. The early data tells you if regain is starting. 3. If you regain >5% of starting weight back within 6 months, restart at a lower dose rather than rebound-cycling.

For HGH specifically: don't stop without a taper plan and ideally medical oversight.

What rebound is NOT

A few things this guide is not warning you about:

• Suppression of the HPG axis — this is a steroid concern, not a peptide concern. Almost no peptides on Pepdex shut down testosterone production.
• Receptor permanent damage — the standard 4-week break fully recovers receptor sensitivity for every peptide on the catalog.
• Acute withdrawal syndromes — peptides don't create the kind of physical dependence that causes seizures, cardiovascular crises, or psychiatric emergencies on stopping.

The "coming off" question is mostly about appetite, sleep, body composition, and the underlying condition being managed — not about chemical dependence or organ-system harm.

Members get full unlocked access to the rest of Pepdex's content + tools — AI Coach (which can answer specific questions about your stack) and Personal Stack tracking. Become a member for $7.99/mo or $80/yr.